ArticleThe Prostate2021

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.

Laura S Graham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.